Identification of human cancers deficient in antigen processing

Intracellular antigens must be processed before presentation to CD8+ T cells by major histocompatibility complex (MHC) class I molecules. Using a recombinant vaccinia virus (Vac) to transiently express the Kd molecule, we studied the antigen processing efficiency of 26 different human tumor lines. Three cell lines, all human small cell lung carcinoma, consistently failed to process endogenously synthesized proteins for presentation to Kd-restricted, Vac-specific T cells. Pulse- chase experiments showed that MHC class I molecules were not transported by these cell lines from the endoplasmic reticulum to the cell surface. This finding suggested that peptides were not available for binding to nascent MHC molecules in the endoplasmic reticulum. Northern blot analysis of these cells revealed low to nondetectable levels of mRNAs for MHC-encoded proteasome components LMP-7 and LMP-2, as well as the putative peptide transporters TAP-1 and TAP-2. Treatment of cells with interferon gamma enhanced expression of these mRNAs and reversed the observed functional and biochemical deficits. Our findings suggest that downregulation of antigen processing may be one of the strategies used by tumors to escape immune surveillance. Potential therapeutic applications of these findings include enhancing antigen processing at the level of the transcription of MHC-encoded proteasome and transporter genes.

[1]  P. Cresswell,et al.  Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules , 1992, Nature.

[2]  J. Neefjes,et al.  Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation , 1992, Nature.

[3]  J. Bodmer,et al.  Nomenclature for factors of the HLA system, 1991 , 1992, Human immunology.

[4]  A. Goldberg,et al.  Proteolysis, proteasomes and antigen presentation , 1992, Nature.

[5]  N. Huskisson,et al.  Effect of polymorphism of an MHC-linked transporter on the peptides assembled in a class I molecule , 1992, Nature.

[6]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[7]  J. Strominger,et al.  Two putative subunits of a peptide pump encoded in the human major histocompatibility complex class II region. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Günter J. Hämmerling,et al.  Subunit of the '20S' proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex , 1991, Nature.

[9]  S. Beck,et al.  A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC , 1991, Nature.

[10]  J. Monaco,et al.  Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes , 1991, Nature.

[11]  A. Asher,et al.  Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. , 1991, Journal of immunology.

[12]  M. Luscher,et al.  Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis , 1991, Nature.

[13]  B. Moss,et al.  Vaccinia virus: a tool for research and vaccine development , 1991, Science.

[14]  T. Boon,et al.  The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice , 1991, The Journal of experimental medicine.

[15]  T. Elliott,et al.  Peptide-induced conformational change of the class I heavy chain , 1991, Nature.

[16]  P. Greenberg.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.

[17]  J. Monaco,et al.  MHC class II region encoding proteins related to the muKidrug resistance family of transmembrane transporters , 1990, Nature.

[18]  J. Monaco,et al.  Transport protein genes in the murine MHC: possible implications for antigen processing. , 1990, Science.

[19]  R. Demars,et al.  A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway , 1990, Nature.

[20]  S. Beck,et al.  Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters , 1990, Nature.

[21]  S. Nathenson,et al.  Isolation of an endogenously processed immunodominant viral peptide from the class I H–2Kb molecule , 1990, Nature.

[22]  Hidde L. Ploegh,et al.  Empty MHC class I molecules come out in the cold , 1990, Nature.

[23]  Timothy A. Springer,et al.  Adhesion receptors of the immune system , 1990, Nature.

[24]  T. Elliott,et al.  Assembly of MHC class I molecules analyzed in vitro , 1990, Cell.

[25]  P. Cresswell,et al.  Presentation of viral antigen controlled by a gene in the major histocompatibility complex , 1990, Nature.

[26]  M. Bevan,et al.  Defective presentation of endogenous antigen by a cell line expressing class I molecules. , 1990, Science.

[27]  S. Rosenberg,et al.  Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. , 1990, Journal of immunology.

[28]  J. Yewdell,et al.  Antigen presentation requires transport of MHC class I molecules from the endoplasmic reticulum. , 1990, Science.

[29]  G. Jay,et al.  Suppression of MHC class I RNA in highly oncogenic cells occurs at the level of transcription initiation. , 1989, Journal of immunology.

[30]  H. Ljunggren,et al.  Association of class I major histocompatibility heavy and light chains induced by viral peptides , 1989, Nature.

[31]  J. Yewdell,et al.  Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes. , 1989, Science.

[32]  R. Kerbel,et al.  Failure of expression of class I major histocompatibility antigens to alter tumor immunogenicity of a spontaneous murine carcinoma. , 1989, Journal of the National Cancer Institute.

[33]  A. Townsend,et al.  Antigen recognition by class I-restricted T lymphocytes. , 1989, Annual review of immunology.

[34]  B. Elliott,et al.  Perspectives on the role of MHC antigens in normal and malignant cell development. , 1989, Advances in cancer research.

[35]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[36]  C. Balch,et al.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor , 1988, The Journal of experimental medicine.

[37]  J. Yewdell,et al.  Monoclonal antibodies localize events in the folding, assembly, and intracellular transport of the influenza virus hemagglutinin glycoprotein , 1988, Cell.

[38]  H. Schreiber,et al.  Unique tumor-specific antigens. , 1988, Annual review of immunology.

[39]  S. Rosenberg,et al.  Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection , 1987, The Journal of experimental medicine.

[40]  M. A. Saper,et al.  The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens , 1987, Nature.

[41]  J. Levin,et al.  Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses. , 1987, Virology.

[42]  B. Coupar,et al.  Immune responses to H-2Kd antigen expressed by recombinant vaccinia virus. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[44]  J. Minna,et al.  Paucity of beta 2-microglobulin expression on small cell lung cancer, bronchial carcinoids and certain other neuroendocrine tumors. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[45]  B. Moss,et al.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques , 1985, Molecular and cellular biology.

[46]  J. Minna,et al.  Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer , 1985, The Journal of experimental medicine.

[47]  K. Isselbacher,et al.  Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. , 1985, Science.

[48]  J. Seidman,et al.  The expression of major histocompatibility antigens under metallothionein gene promoter control. , 1985, Journal of immunology.

[49]  P. Greenberg,et al.  H-2 restriction of adoptive immunotherapy of advanced tumors. , 1981, Journal of immunology.

[50]  K. Shimizu,et al.  Role of different T cells sets in the rejection of syngeneic chemically induced tumors. , 1979, Journal of immunology.

[51]  M. Torres,et al.  Nomenclature for factors of the HLA system. , 2011, Bulletin of the World Health Organization.

[52]  G. Klein,et al.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. , 1960, Cancer research.